Treatment of cutaneous leishmaniasis with aminosidine (paromomycin) ointment: double-blind, randomized trial in the Islamic Republic of Iran
- PMID: 12856053
- PMCID: PMC2572463
Treatment of cutaneous leishmaniasis with aminosidine (paromomycin) ointment: double-blind, randomized trial in the Islamic Republic of Iran
Abstract
Objective: To compare the parasitological and clinical efficacy of four weeks versus two weeks of treatment with aminosidine (paromomycin) ointment in patients with cutaneous leishmaniasis caused by Leishmania major in the Islamic Republic of Iran.
Methods: Double-blind, randomized trial of four weeks of aminosidine ointment (n = 108) vs two weeks of aminosidine ointment and two weeks of placebo (n = 108). Patients were assessed on days 15, 29, 45, and 105 for clinical cures and clinical and parasitological cures.
Findings: Four weeks' treatment gave significantly better cure rates than two weeks' treatment: on day 29, there were 80/108 (74%) vs 64/108 (59%) clinical cures (P = 0.05) and 47 (44%) vs 26 (24%) clinical and parasitological cures (P = 0.005). By day 45, fewer patients who received four weeks' treatment had required rescue treatment with antimonials than those who received two weeks' treatment: 20 (19%) vs 36 (33%) (P = 0.02). On day 105, the results still favoured those who had been allocated four weeks of active treatment, but the differences were no longer as clearly significant. No side-effects were observed or reported.
Conclusion: Approximately two-thirds of patients given ointment for four weeks were cured clinically. Although about half of those cured might have recovered spontaneously even without treatment, four weeks of aminosidine ointment could become the first-line treatment for uncomplicated cutaneous leishmaniasis due to L. major, with antimonials needed in only the one-third of patients not cured by the end of treatment with aminosidine. This would considerably reduce the costs and side-effects associated with antimonial drugs.
Similar articles
-
A randomized, placebo-controlled trial of a two-week regimen of aminosidine (paromomycin) ointment for treatment of cutaneous leishmaniasis in Iran.Am J Trop Med Hyg. 1995 Dec;53(6):648-51. doi: 10.4269/ajtmh.1995.53.648. Am J Trop Med Hyg. 1995. PMID: 8561269 Clinical Trial.
-
Efficacy of paromomycin ointment in the treatment of cutaneous leishmaniasis: results of a double-blind, randomized trial in Isfahan, Iran.Ann Trop Med Parasitol. 2005 Jan;99(1):3-9. doi: 10.1179/136485905X16372. Ann Trop Med Parasitol. 2005. PMID: 15701249 Clinical Trial.
-
Treatment of cutaneous leishmaniasis with 20% paromomycin ointment.J Eur Acad Dermatol Venereol. 1999 Nov;13(3):214-7. doi: 10.1111/j.1468-3083.1999.tb00886.x. J Eur Acad Dermatol Venereol. 1999. PMID: 10642059
-
Cutaneous leishmaniasis treatment.Travel Med Infect Dis. 2007 May;5(3):150-8. doi: 10.1016/j.tmaid.2006.09.004. Epub 2006 Oct 31. Travel Med Infect Dis. 2007. PMID: 17448941 Review.
-
Cutaneous Leishmaniasis in an American Adolescent Returning From Israel.J Pediatric Infect Dis Soc. 2018 Aug 17;7(3):e178-e181. doi: 10.1093/jpids/piy045. J Pediatric Infect Dis Soc. 2018. PMID: 29878238 Review.
Cited by
-
In Commemoration of Dr. Farrokh Modabber: An Iranian Pioneer of Cellular Immunology, and Leishmaniases Vaccine Research in Iran and the World.Arch Iran Med. 2024 Sep 1;27(9):530-537. doi: 10.34172/aim.28959. Epub 2024 Sep 1. Arch Iran Med. 2024. PMID: 39465529 Free PMC article.
-
Treatment of Cutaneous Leishmaniasis and Insights into Species-Specific Responses: A Narrative Review.Infect Dis Ther. 2022 Apr;11(2):695-711. doi: 10.1007/s40121-022-00602-2. Epub 2022 Feb 22. Infect Dis Ther. 2022. PMID: 35192172 Free PMC article. Review.
-
Evaluation of the Interventional Approaches in the Management of Cutaneous Leishmaniasis in Jazan: An Observational Study.Ann Dermatol. 2018 Oct;30(5):575-580. doi: 10.5021/ad.2018.30.5.575. Epub 2018 Aug 28. Ann Dermatol. 2018. PMID: 33911481 Free PMC article.
-
Therapeutic advances in the topical treatment of cutaneous leishmaniasis: A review.PLoS Negl Trop Dis. 2021 Mar 3;15(3):e0009099. doi: 10.1371/journal.pntd.0009099. eCollection 2021 Mar. PLoS Negl Trop Dis. 2021. PMID: 33657097 Free PMC article. Review.
-
CpG ODN D35 improves the response to abbreviated low-dose pentavalent antimonial treatment in non-human primate model of cutaneous leishmaniasis.PLoS Negl Trop Dis. 2020 Feb 28;14(2):e0008050. doi: 10.1371/journal.pntd.0008050. eCollection 2020 Feb. PLoS Negl Trop Dis. 2020. PMID: 32109251 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources